Credo Life Science
Posted on 27th January 2022
Choosing the Right Pancreatin Pellets Manufacturer for Global Pharmaceutical Needs
Global pharmaceutical companies sourcing pancreatin pellets face a narrower field of genuinely qualified manufacturers than most other pellet categories, given the enzyme’s unusual sensitivity to standard processing conditions.
Understanding the Global Demand for Pancreatin Pellets
Pancreatin is used to treat pancreatic enzyme insufficiency arising from conditions such as pancreatitis, cystic fibrosis, and post-surgical pancreatectomy, creating consistent global demand for reliable, enteric-coated enzyme formulations across multiple regulated markets.
What Sets Qualified Manufacturers Apart
Because water-based processing degrades enzyme activity, qualified manufacturers must demonstrate genuine expertise in non-aqueous or carefully controlled processing methods, along with enteric coating techniques that preserve potency through gastric transit.
Regulatory Documentation for Global Markets
Global buyers should confirm WHO-GMP certification, review DMF filings relevant to their target markets, and request stability data specifically demonstrating enzyme potency retention — a different validation requirement than standard chemical API stability testing.
Evaluating Manufacturing Track Record
Ask prospective manufacturers for examples of pancreatin or comparable enzyme formulations they’ve successfully scaled from pilot to commercial production, since enzyme-based formulations often behave differently at scale than typical small-molecule APIs.
The Cost of Choosing the Wrong Partner
Because pancreatin formulation demands such specialized expertise, working with a manufacturer lacking direct experience can lead to batches with reduced enzyme activity, inconsistent release performance, or stability failures discovered only after significant time and investment have already been committed.
Credo Life Sciences: Addressing This Specialized Need
Credo Life Sciences, incorporated in 2014 in Hyderabad, includes Pancreatin EC Pellets within its active R&D pipeline, reflecting a deliberate focus on this specialized formulation category. Backed by WHO-GMP certification and DMF documentation aligned with USFDA, EU, and WHO-GMP standards, the company brings the kind of enteric-coating expertise this challenging molecule requires.
Conclusion: Global pharmaceutical companies sourcing pancreatin pellets should prioritize manufacturers with demonstrated, molecule-specific expertise over general pellet manufacturing capability alone.